Cellular Uptake of siRNA-Loaded Nanocarriers to Knockdown PD-L1: Strategies to Improve T-cell Functions

Adoptive cell therapy: past, present and future

(2017) Jonathan E Cohen et al.   Immunotherapy

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Silica-based nanocapsules: synthesis, structure control and biomedical applications

(2015) Yu Zhang et al.   CHEMICAL SOCIETY REVIEWS

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

(2015) Daniel Sanghoon Shin et al.   CURRENT OPINION IN IMMUNOLOGY

Cancer immunotherapy: Strategies for personalization and combinatorial approaches

(2015) Vishwanath Sathyanarayanan et al.   Molecular Oncology

Ovarian Cancer Immunotherapy Using PD-L1 siRNA Targeted Delivery from Folic Acid-Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing

(2015) Pei Yun Teo et al.   Advanced Healthcare Materials

Current advances in T-cell-based cancer immunotherapy

(2014) Mingjun Wang et al.   Immunotherapy

Advances in siRNA delivery to T-cells: potential clinical applications for inflammatory disease, cancer and infection

(2013) Michael Freeley et al.   BIOCHEMICAL JOURNAL

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Regulation of TRIB3 mRNA and Protein in Breast Cancer

(2012) Marloes Wennemers et al.   PLoS One

siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions

(2011) K Iwamura et al.   GENE THERAPY

PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice

(2010) Scott N. Mueller et al.   JOURNAL OF CLINICAL INVESTIGATION

Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy

(2009) S. Samarasinghe et al.   BLOOD